Zonal-Specific Risk Stratification Integrating Magnetic Resonance Imaging and Prostate-Specific Antigen Density for Optimizing Prostate Biopsy Selection in Prostate-Specific Antigen 4-20 ng/mL Patients.
[OBJECTIVE] To explore the stratification differences of MRI and prostate-specific antigen (PSA) density (PSAD) in the peripheral zone (PZ) and transition zone (TZ) lesions, in order to optimize the b
- p-value p < 0.05
APA
Yang L, Wang X, et al. (2026). Zonal-Specific Risk Stratification Integrating Magnetic Resonance Imaging and Prostate-Specific Antigen Density for Optimizing Prostate Biopsy Selection in Prostate-Specific Antigen 4-20 ng/mL Patients.. The Prostate, 86(2), 236-248. https://doi.org/10.1002/pros.70075
MLA
Yang L, et al.. "Zonal-Specific Risk Stratification Integrating Magnetic Resonance Imaging and Prostate-Specific Antigen Density for Optimizing Prostate Biopsy Selection in Prostate-Specific Antigen 4-20 ng/mL Patients.." The Prostate, vol. 86, no. 2, 2026, pp. 236-248.
PMID
41046454
Abstract
[OBJECTIVE] To explore the stratification differences of MRI and prostate-specific antigen (PSA) density (PSAD) in the peripheral zone (PZ) and transition zone (TZ) lesions, in order to optimize the biopsy decision for patients with PSA 4-20 ng/mL.
[METHODS] This retrospective study analyzed 1524 patients undergoing MRI and biopsy. Lesions were grouped by PZ and TZ and the differences of PSAD within the subgroups were explored. A zonal-specific risk matrix was constructed by integrating the Prostate Imaging Reporting and Data System (PI-RADS) categories and PSAD in overall, PZ, and TZ cohorts. Low or high-threshold pathway was constructed by 10% or 30% clinically significant prostate cancer (csPCa) probability for PZ and TZ. Six biopsy pathways were then formed and evaluated by the biopsy avoidance, csPCa detection, and positive predictive value (PPV). Finally, decision curve analysis (DCA) was employed to evaluate the net benefit associated with each pathway.
[RESULTS] PZ lesions exhibited higher PSAD than TZ counterparts in equivalent PI-RADS categories (p < 0.05). In the risk matrix, for PI-RADS 1-2 lesions, TZ required PSAD ≥ 0.15 ng/mL/cm while PZ ≥ 0.20 ng/mL/cm to achieve > 10% csPCa risk. For PI-RADS 3 lesions, thresholds were ≥ 0.15 ng/mL/cm (TZ) and ≥ 0.20 ng/mL/cm (PZ) to trigger biopsy at > 30% csPCa risk. Among six pathways, the "PZ high + TZ high" pathway (PSAD ≥ 0.20 ng/mL/cm for PZ and ≥ 0.15 ng/mL/cm for TZ in PI-RADS 3) achieved optimal balance, detecting 86.6% of csPCa while avoiding 48.0% of unnecessary biopsies, with a PPV of 69.1% (F1-score = 0.77). DCA confirmed superior net clinical benefit for this pathway at ≥ 20% risk thresholds.
[CONCLUSION] In the risk stratification of MRI and PSAD, considering zonal specific of the lesion is helpful to improve biopsy decisions in patients with PSA 4-20 ng/mL.
[METHODS] This retrospective study analyzed 1524 patients undergoing MRI and biopsy. Lesions were grouped by PZ and TZ and the differences of PSAD within the subgroups were explored. A zonal-specific risk matrix was constructed by integrating the Prostate Imaging Reporting and Data System (PI-RADS) categories and PSAD in overall, PZ, and TZ cohorts. Low or high-threshold pathway was constructed by 10% or 30% clinically significant prostate cancer (csPCa) probability for PZ and TZ. Six biopsy pathways were then formed and evaluated by the biopsy avoidance, csPCa detection, and positive predictive value (PPV). Finally, decision curve analysis (DCA) was employed to evaluate the net benefit associated with each pathway.
[RESULTS] PZ lesions exhibited higher PSAD than TZ counterparts in equivalent PI-RADS categories (p < 0.05). In the risk matrix, for PI-RADS 1-2 lesions, TZ required PSAD ≥ 0.15 ng/mL/cm while PZ ≥ 0.20 ng/mL/cm to achieve > 10% csPCa risk. For PI-RADS 3 lesions, thresholds were ≥ 0.15 ng/mL/cm (TZ) and ≥ 0.20 ng/mL/cm (PZ) to trigger biopsy at > 30% csPCa risk. Among six pathways, the "PZ high + TZ high" pathway (PSAD ≥ 0.20 ng/mL/cm for PZ and ≥ 0.15 ng/mL/cm for TZ in PI-RADS 3) achieved optimal balance, detecting 86.6% of csPCa while avoiding 48.0% of unnecessary biopsies, with a PPV of 69.1% (F1-score = 0.77). DCA confirmed superior net clinical benefit for this pathway at ≥ 20% risk thresholds.
[CONCLUSION] In the risk stratification of MRI and PSAD, considering zonal specific of the lesion is helpful to improve biopsy decisions in patients with PSA 4-20 ng/mL.
MeSH Terms
Humans; Male; Prostatic Neoplasms; Prostate-Specific Antigen; Retrospective Studies; Middle Aged; Aged; Magnetic Resonance Imaging; Risk Assessment; Prostate; Biopsy; Image-Guided Biopsy
같은 제1저자의 인용 많은 논문 (5)
- Generational trends in reproductive factors among women in the US: implications for breast cancer incidence.
- Prediction of high-risk factor in early-stage lung cancer: micropapillary adenocarcinoma.
- Comprehensive treatment for intracranial invasive sinonasal intestinal-type adenocarcinoma with a focus on radiotherapy dosage and immunological combination therapy: A case report.
- Cancer-associated fibroblasts-derived exosomes in colorectal cancer progression: Mechanism and therapeutic opportunities.
- Effects of Preoperative Mindfulness Training Combined With Active Breathing and Circulation Exercises on Pulmonary Function Recovery in Lung Cancer Patients After Lobectomy.